BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 15089764)

  • 21. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia.
    Falkson G; Coccia-Portugal MA; Vorobiof DA; Terblanche AP; Dreyer R
    Am J Clin Oncol; 1986 Aug; 9(4):311-4. PubMed ID: 3463190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience.
    Mazza P; Prudenzano A; Amurri B; Palazzo G; Pisapia G; Stani L; Pricolo G
    Bone Marrow Transplant; 2003 Aug; 32(4):433-6. PubMed ID: 12900781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
    Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
    Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
    Saikia TK; Bakshi A; Bhagwat R; Tawde S; Nair R; Nair CN; Parikh PM
    Natl Med J India; 2005; 18(1):12-5. PubMed ID: 15835484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukemia.
    Kerridge I; Lowe M; Seldon M; Enno A; Deveridge S
    Arch Intern Med; 1997 Aug 11-25; 157(15):1753-7. PubMed ID: 9250237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of all-trans-retinoic acid alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukaemia.
    Colović MD; Janković GM; Elezović I; Vidović A; Bila JS; Novak A; Babić D
    Med Oncol; 1997 Jun; 14(2):65-72. PubMed ID: 9330265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
    Latagliata R; Breccia M; Fazi P; Iacobelli S; Martinelli G; Di Raimondo F; Sborgia M; Fabbiano F; Pirrotta MT; Zaccaria A; Amadori S; Caramatti C; Falzetti F; Candoni A; Mattei D; Morselli M; Alimena G; Vignetti M; Baccarani M; Mandelli F
    Br J Haematol; 2008 Dec; 143(5):681-9. PubMed ID: 18950458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy in canine acute megakaryoblastic leukemia: a case report and review of the literature.
    Willmann M; Müllauer L; Schwendenwein I; Wolfesberger B; Kleiter M; Pagitz M; Hadzijusufovic E; Shibly S; Reifinger M; Thalhammer JG; Valent P
    In Vivo; 2009; 23(6):911-8. PubMed ID: 20023232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period.
    Ferrari A; Annino L; Crescenzi S; Romani C; Mandelli F
    Leukemia; 1995 Oct; 9(10):1643-7. PubMed ID: 7564503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
    Sperr WR; Piribauer M; Wimazal F; Fonatsch C; Thalhammer-Scherrer R; Schwarzinger I; Geissler K; Knöbl P; Jäger U; Lechner K; Valent P
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3965-71. PubMed ID: 15217926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of 6-mercaptopurine, vincristine, methotrexate, and prednisone in resistant or relapsed acute nonlymphoid leukemia.
    Leone G; Pagano L; Marra R; Landolfi R; Cudillo L; Storti S; Mango G; Alfano G; D'Onofrio G
    Cancer Treat Rep; 1987; 71(7-8):751-3. PubMed ID: 3607785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acute promyelocytic leukemia: a single institution experience.
    Ruiz-Argüelles GJ; Morales-Toquero A; Gómez-Rangel JD; López-Martínez B; Ruiz-Delgado GJ; Reyes-Núñez V
    Rev Invest Clin; 2005; 57(3):415-9. PubMed ID: 16187701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy.
    Kanemura N; Tsurumi H; Kasahara S; Hara T; Yamada T; Sawada M; Goto N; Kitagawa J; Shimizu M; Oyama M; Moriwaki H
    Hematol Oncol; 2008 Mar; 26(1):33-8. PubMed ID: 17918772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acute leukemia. Case material and therapeutic results].
    Paolino W; Resegotti L; Rossi M; Infelise V; Degani GF
    Minerva Med; 1975 May; 66(35):1642-52. PubMed ID: 1055305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.